Brainomics & Bridge Biotherapeutics, Inc. Publicizes Partnership to Use Brainomics’ AI-Powered E-ILD Software program for Automated Evaluation of Idiopathic Pulmonary Fibrosis (IPF)

This partnership will deal with quantitative evaluation of imaging information by Brainomics AI software program (e-ILD) inside a part 2 examine of the novel autotaxin inhibitor, BBT-877, in idiopathic pulmonary fibrosis (IPF). oxford, england, September 7, 2022 /PRNewswire/ — Brainomics, an AI-powered medtech options firm, and Bridge Biotherapeutics, Inc., a South Korean clinical-stage biotechnology firm … Read more